Which of the following is the Center for Drug Evaluation and Research abbreviated as?

Prepare for the US Regulatory Affairs Certification (RAC) Exam with our comprehensive study materials. Master multiple choice questions and in-depth explanations. Boost your confidence for exam day!

Multiple Choice

Which of the following is the Center for Drug Evaluation and Research abbreviated as?

Explanation:
The Center for Drug Evaluation and Research is abbreviated as CDER. This center is part of the U.S. Food and Drug Administration (FDA) and is responsible for ensuring that drugs are safe and effective for public use. CDER plays a crucial role in reviewing new drug applications, overseeing the approval processes for prescription and over-the-counter drugs, and monitoring the safety of drugs on the market. The other abbreviations represent different entities within the FDA: CBER stands for the Center for Biologics Evaluation and Research, CDRH is the Center for Devices and Radiological Health, and CFR refers to the Code of Federal Regulations, which contains the regulations governing various aspects of federal law including those related to drug and device oversight. Understanding these distinctions is vital for anyone involved in regulatory affairs within the pharmaceutical and healthcare sectors.

The Center for Drug Evaluation and Research is abbreviated as CDER. This center is part of the U.S. Food and Drug Administration (FDA) and is responsible for ensuring that drugs are safe and effective for public use. CDER plays a crucial role in reviewing new drug applications, overseeing the approval processes for prescription and over-the-counter drugs, and monitoring the safety of drugs on the market.

The other abbreviations represent different entities within the FDA: CBER stands for the Center for Biologics Evaluation and Research, CDRH is the Center for Devices and Radiological Health, and CFR refers to the Code of Federal Regulations, which contains the regulations governing various aspects of federal law including those related to drug and device oversight. Understanding these distinctions is vital for anyone involved in regulatory affairs within the pharmaceutical and healthcare sectors.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy